Thus, our data highlight a crucial role of expression status of ZIP10 in affecting the response of thyroid cancer cells to mannose, and offer a mechanistic rationale for exploring clinical use of mannose in thyroid cancer therapy, especially combining with chemotherapy, radiotherapy or immunotherapy. This evidence concerns the gene SLC39A10 and thyroid gland carcinoma.